Chul Kim, MD, MPH

Explore how brain metastases and TP53 co-mutations shape EGFR-mutant NSCLC first-line care, including intracranial control, radiation sequencing, and key trial insights.

Experts weigh first-line EGFR lung cancer options, from osimertinib alone to combos, with guidance for brain mets and TP53 high-risk patients.

Rapid readout: Real-world lifileucel TIL shows 44% responses in metastatic melanoma, favoring early referral and manageable IL-2 toxicity.

Chul Kim, MD, MPH, discusses the impact of optimizing rare targets in lung cancer, highlighting the FDA approval of repotrectinib in ROS1-positive disease.

Chul Kim, MD, MPH, an attending physician at MedStar Health and an assistant professor of medicine at Georgetown University, discusses overcoming mechanisms of resistance to TKIs in non–small cell lung cancer (NSCLC).